concept

RB

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about RB: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2519Connections

26Hypotheses

0Analyses

50Outgoing

50Incoming

2Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	RB
Linked Hypotheses	5 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    RB["RB"]
    style RB fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    RB -->|"interacts"| Als["Als"]
    RB -.->|"inhibits"| Atherosclerosis["Atherosclerosis"]
    RB -->|"activates"| Dementia["Dementia"]
    RB -->|"activates"| Alzheimer["Alzheimer"]
    RB -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
    RB -->|"interacts"| Parkinson["Parkinson"]
    MTOR([MTOR]) -.->|"inhibits"| RB
    AMPK([AMPK]) -->|"interacts"| RB
    ABCA1([ABCA1]) -->|"interacts"| RB
    P2RY12([P2RY12]) -.->|"inhibits"| RB
    ABCG1([ABCG1]) -->|"interacts"| RB
    ALS([ALS]) -->|"interacts"| RB
    MAO([MAO]) -.->|"inhibits"| RB
    ULK1([ULK1]) -->|"interacts"| RB
    ATP([ATP]) -->|"interacts"| RB
    ACTB([ACTB]) -->|"interacts"| RB

Outgoing (446)

Target	Relation	Type	Str
Depression	inhibits	disease	0.60
Amyotrophic Lateral Sclerosis	causes	disease	0.60
Amyotrophic Lateral Sclerosis	inhibits	disease	0.60
Bipolar	activates	disease	0.60
Alzheimer	transports	disease	0.60
Glioblastoma	expressed_in	disease	0.60
Fibrosis	interacts_with	disease	0.60
Neurodegeneration	inhibits	disease	0.60
Anxiety	regulates	disease	0.60
Anxiety	protects_against	disease	0.60
Neuropathy	causes	disease	0.60
Aging	biomarker_for	disease	0.60
Autism	activates	disease	0.60
Aging	interacts_with	disease	0.60
Neurodegeneration	interacts_with	disease	0.60
Multiple Sclerosis	therapeutic_target	disease	0.60
Neuroinflammation	causes	disease	0.60
Tauopathy	expressed_in	disease	0.60
Cancer	activates	disease	0.60
Glioblastoma	therapeutic_target	disease	0.60
Atherosclerosis	activates	disease	0.60
Depression	protects_against	disease	0.60
Cancer	interacts_with	disease	0.60
Neurodegeneration	biomarker_for	disease	0.60
Alzheimer	therapeutic_target	disease	0.60
Frontotemporal Dementia	causes	disease	0.60
Als	protects_against	disease	0.60
Atherosclerosis	associated_with	disease	0.60
Als	biomarker_for	disease	0.60
Ferroptosis	biomarker_for	disease	0.60
Als	causes	disease	0.60
Ischemia	causes	disease	0.60
Dementia	causes	disease	0.60
Ferroptosis	causes	disease	0.60
Vascular Dementia	causes	disease	0.60
Alzheimer	causes	disease	0.60
Obesity	regulates	disease	0.60
Dementia	expressed_in	disease	0.60
Diabetes	regulates	disease	0.60
Amyotrophic Lateral Sclerosis	therapeutic_target	disease	0.60
Atherosclerosis	regulates	disease	0.60
Ischemia	protects_against	disease	0.60
Neuroinflammation	regulates	disease	0.60
Parkinson	therapeutic_target	disease	0.60
Alzheimer	regulates	disease	0.60
Cancer	causes	disease	0.60
Neurodegeneration	causes	disease	0.60
Aging	protects_against	disease	0.60
Aging	expressed_in	disease	0.60
Amyotrophic Lateral Sclerosis	interacts_with	disease	0.60

Incoming (2073)

Source	Relation	Type	Str
AMPK	activates	gene	0.60
LDHA	activates	gene	0.60
PHAGOCYTOSIS	activates	gene	0.60
DEMENTIA	activates	gene	0.60
RNA	activates	gene	0.60
COMPLEMENT	activates	gene	0.60
MICROGLIA	activates	gene	0.60
ALZHEIMER	activates	gene	0.60
NUCLEOPHAGY	interacts_with	gene	0.60
PARKINSON	interacts_with	gene	0.60
ROS	interacts_with	gene	0.60
ALZHEIMER	interacts_with	gene	0.60
RAS	interacts_with	gene	0.60
APOPTOSIS	interacts_with	gene	0.60
MITOPHAGY	interacts_with	gene	0.60
PGAM5	interacts_with	gene	0.60
PRESENILIN	interacts_with	gene	0.60
ATG	interacts_with	gene	0.60
SESTRIN2	interacts_with	gene	0.60
CATALASE	interacts_with	gene	0.60
DEMENTIA	interacts_with	gene	0.60
NLR	interacts_with	gene	0.60
ALS	activates	gene	0.60
DNA	activates	gene	0.60
ATG	activates	gene	0.60
AUTOPHAGY	activates	gene	0.60
MAPK	therapeutic_target	gene	0.60
AUTOPHAGY	therapeutic_target	gene	0.60
METTL3	therapeutic_target	gene	0.60
ENDOSOMES	interacts_with	gene	0.60
MITOCHONDRIA	regulates	gene	0.60
TRPML1	regulates	gene	0.60
RNA	regulates	gene	0.60
MTORC1	regulates	gene	0.60
LYSOSOME	activates	gene	0.60
AUTOPHAGY	regulates	gene	0.60
CYTOKINES	activates	gene	0.60
NR3C2	activates	gene	0.60
IL12	activates	gene	0.60
RUNX2	activates	gene	0.60
PD-1	activates	gene	0.60
IL-17	regulates	gene	0.60
COMPLEMENT	regulates	gene	0.60
MICROGLIA	regulates	gene	0.60
EXOSOMES	activates	gene	0.60
APP/PS1	associated_with	gene	0.60
DEMENTIA	therapeutic_target	gene	0.60
CX43	associated_with	gene	0.60
ASTROCYTE	therapeutic_target	gene	0.60
FERROPTOSIS	activates	gene	0.60

Targeting Hypotheses (26)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P	0.868	als	-
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate	0.785	-	Do β-amyloid plaques and neurofibrillary
Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determ	0.738	neuroinflammation	How do B cells mechanistically orchestra
VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottl	0.700	neurodegeneration	-
AQP4-Dependent Astrocyte Swelling Exacerbates Excitotoxic Ne	0.670	neurodegeneration	What are the specific molecular mechanis

Vascular mural cell degeneration precedes and exacerbates pa	0.661	alzheimers	SEA-AD Single-Cell Analysis: Cell-Type V
early PD proteogenomic hubs that are both causal enough and	0.626	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Sex-Specific Microglial States in Amyloi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Genetic Aging Landscape Variants and Epi
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	DPP6 GWAS Signal: Cell-Type Regulatory N
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Causal Sequence of TDP-43 Nuclear Cleara
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Proteogenomic Network Hubs as Druggable
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Biophysical Determinants Shifting FUS/TD
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	VEGF Family GWAS Signals and Cerebrovasc
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	CCL2-CCR2 Axis at NMJ: Mechanism of Sele
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Non-Neuronal Transcriptional Changes Pre
Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Met	0.597	neuroinflammation	What molecular mechanisms determine whet
Parthenolide perturbs adenosine transport or metabolism upst	0.506	neuropharmacology	How does parthenolide specifically modul
REV-ERB Agonist Microglial Deactivation	0.455	chronobiology	Can circadian interventions reverse micr
Phosphatidylserine Decarboxylase (PISD) Restoration to Corre	0.342	lipidomics	Lipid metabolism dysregulation in Alzhei
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacolog	0.308	metabolomics	Metabolomic signatures of neurodegenerat
Compensatory RBP Expression Therapy	0.000	-	RNA binding protein dysregulation across
Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotecti	0.000	-	Mitochondrial transfer between astrocyte
Proteostasis Network Activation for RBPs	0.000	-	RNA binding protein dysregulation across

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
IL-10 deficiency and VLC ceramide accumulation in inflammatory bowel d	validation	inflammatory bowel disease	0.900	0.00	IL-10 knockout mice	proposed	N/A
Irisin effects on angiogenesis in human endothelial cells	exploratory	bone fracture	0.900	0.00	human umbilical vein endotheli	proposed	N/A

Related Papers (8)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Pathophysiology of Primary Familial Brain Calcification. [PMID:41212990]	Keller A	Annual review of physiology	2026
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in h [PMID:40902811]	Wang Y, Zhang Z, Cao L, Huang S, Huang X	J Ethnopharmacol	2026
Based on network pharmacology and experiments to investigate the inhibitory effe [PMID:41308710]	Yang X, Xiao JH, Li X, Liu RM, Yuan Q	J Ethnopharmacol	2026
Novel insights into meningioma brain invasion with spatial transcriptomic profil [PMID:41486296]	Maier AD, Laurentiussen CO, Michaelsen S	Acta Neuropathol Commun	2026
Brain vascular stability relies on PAK2-cilia-PDGF-BB-HSPGs on basolateral side [PMID:41490797]	Prabhudesai S, Thirugnanam K, Song X, Ya	Life Sci Alliance	2026
Plasma platelet-derived growth factor receptor-β decrease correlates with blood- [PMID:41530860]	Li J, Li A, Ye C, Zhang L, Jiang M et al	Mol Neurodegener	2026
FOXF2 regulates pericyte-endothelial signaling required for vascular homeostasis [PMID:41680210]	Sun F, Zhao Y, Do J, Cheng P, Li E et al	Nat Commun	2026
Loss of Pericyte Exacerbates Alzheimer's Disease-Associated Retinal Pathology. [PMID:41814129]	Hai-Chao C, Fu-Lin G, Jia-Xin C, Yi-Shu	Clinical & experimental ophtha	2026

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning RB in their description or question text

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.661 · alzheimers · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

early PD proteogenomic hubs that are both causal enough and accessible enough to

Score: 0.626 · neurodegeneration · 2026-04-28

early PD proteogenomic hubs that are both causal enough and accessible enough to perturb should produce a measurable pro